What are the three related projects being announced by ARPA-H to improve clinical trial infrastructure?
The three related projects focus on: 1) using AI to speed up the activation of more clinical trial sites to increase patient access to experimental drugs; 2) improving clinical trial data infrastructure; and 3) helping patients with complex cancers benefit from their own data and better navigate the care system.
Q&A ID b207da80-71a4-4aa4-9182-d30b202824c5
According to HHS, what are the current costs, timelines, and failure rates associated with drug development?
Currently, developing a drug can take longer than a decade and cost approximately $2 billion, with more than 90% of drug candidates failing.
Q&A ID a36b1c09-10e9-497c-ab30-3a519648e161
How is the SURPASS program structured in terms of participant selection and duration?
The initiative under ARPA-H will solicit ideas from "teams" that include a drug sponsor, with winners selected through a bidding process. These winning teams will receive funding and support over a period of five years.
Q&A ID f0c5fb48-2fea-4219-9241-6ff6e7c309a9
What are the three technical areas of innovation that ARPA-H is seeking proposals for under the SURPASS program?
ARPA-H is looking for proposals that innovate in three specific areas: phaseless trials that allow for faster trials with fewer patients, the ability to analyze data in real time during the trial rather than only at the end, and the use of automation to reduce inefficiencies.
Q&A ID 42200d70-f64a-4fe8-aca5-238a3e897171